stars 1 stars 2 stars 3

BioGenex designs, develops, and commercializes advanced fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. The recent introduction of our eFISHency integrated workflow solution for FISH laboratories and miRNA system for characterization of cancer of unknown primary (CUP) and for undifferentiated tumors is a game changer that has no rival in the industry. Our fully automated molecular pathology work stations are the most advanced system globally. Our customer focused approach, with premier after sales support and excellent technical service, provides the best in class customer care. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for life science research and diagnostics. With a team of accomplished technical, business and customer support professionals, BioGenex strives to reach the pinnacle of the global molecular medicine industry by offering cost-effective solutions for life sciences research and personalized medicine. Additionally, the partnership of BioGenex with top-notch universities, hospitals, and the pharmaceutical and biotechnology industry drives its innovative research and product development activities. The company is also known for its pre- and post-sales customer support that complements the high quality products and solutions offered by the firm.

Website http://www.biogenex.com
Revenue $62.7 million
Funding $649000
Employees 235 (128 on RocketReach)
Founded 1981
Address 48810 Kato Rd Ste 200E, Fremont, California 94538, US
Phone +1 925-275-0550
Fax (510) 824-1490
Technologies
Industry Biotechnology Research, Business Services General, Biotechnology, Diagnostic Equipment, Molecular diagnostics, Business Services, Science and Engineering, Other Pharmaceuticals and Biotechnology, Antibodies, Manufacturing, Immunohistochemistry, IHC Automation, In Situ hybridization, IVD, IHC, ISH, Reagents, Mirna
Web Rank 4 Million
Keywords Molecular Pathology, Molecular Diagnostics, Cancer Diagnostics, Clinical Diagnostics, Personalized Medicine, Cancer Research, Precision Medicine, Tissue Diagnostics, Automated Systems, Pathology Testing, Immunohistochemistry, Diagnostic Solutions, In Situ Hybridization, Lab Automation, Life Science Research, Diagnostic Tools, Workflow Solutions, Medical Devices, Medical Technology
Competitors Roche, Thermo Fisher Scientific, BD, Merck Group, Agilent Technologies, Illumina, Exact Sciences, Bio-Rad Laboratories, QIAGEN +30 more (view full list)
SIC SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 382 Companies, SIC Code 38 Companies
NAICS NAICS Code 325413 Companies, NAICS Code 325 Companies, NAICS Code 541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 54 Companies

BioGenex Questions

The BioGenex annual revenue was $62.7 million in 2026.

Krishan Kalra is the Chairman, CEO and Founder of BioGenex.

128 people are employed at BioGenex.

BioGenex is based in Fremont, California.

The NAICS codes for BioGenex are [325413, 325, 541, 32, 3254, 32541, 54].

The SIC codes for BioGenex are [28, 283, 382, 38].

Top BioGenex Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users